BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, February 23, 2026
Home » Topics » Financings, BioWorld

Financings, BioWorld
Financings, BioWorld RSS Feed RSS

Financings for April 28, 2022

April 28, 2022
Biopharmas raising money in public or private financings, including: Clarus.
Read More
Gold dollar sign

Ashvattha lands $69M series B, Huadong licensing deal

April 27, 2022
By David Ho
Ashvattha Therapeutics Inc. secured $69 million in a series B financing that it said will strengthen its ability to develop hydroxyl dendrimer-based medicines and accelerate efforts to advance its candidates to the clinic.
Read More
Coin stacks, dollar signs and up arrow

Pheast sets table with $76M series A for fighting cancer

April 27, 2022
By Lee Landenberger
Amira Barkal’s grandmother’s long fight against chronic leukemia was the germ of the idea that’s become Pheast Therapeutics Inc., which just closed a series A financing. Her treatment in a clinical trial that gave the world Gleevec (imatinib, Novartis AG) changed both of their lives.
Read More

Financings for April 27, 2022

April 27, 2022
Biopharmas raising money in public or private financings, including: Apertura Gene Therapy, Cellectis, Cytovia, Deciphera, Dermata, Hemoglobin Oxygen, NLS, Okyo, Quantum Genomics, RVAC Medicines, Scynexis, Tempest.
Read More

Financings for April 26, 2022

April 26, 2022
Biopharmas raising money in public or private financings, including: Clarus, Nkarta, Sunshine, Valneva.
Read More
Cancer immunotherapy illustration

Epitopea closes $14M seed round for tumor antigen discovery

April 25, 2022
By Cormac Sheridan
Epitopea Ltd. raised $13.6 million in seed financing to take forward a new cancer immunotherapy platform based on the identification of a new class of tumor-specific antigens encoded by non-canonical genomic sequences.
Read More

Cambridge Innovations raises £225M fund amid high interest in university spinouts

April 25, 2022
By Nuala Moran
Cambridge Innovation Capital (CIC) has closed its oversubscribed Fund II at £225 million (US$287 million) and is moving from its previous model of open-ended investing to a traditional fixed-term venture capital fund. The money will be dedicated to spinouts from Cambridge University, with CIC investing in series A rounds, but also following on as companies mature and their capital requirements increase.
Read More

Financings for April 25, 2022

April 25, 2022
Biopharmas raising money in public or private financings, including: Exogene, Forcefield, Healome, Hemostemix, Hillevax, Immunocore, Mitorx, Salarius, Savara, Scynexis, Syncona, Takeda.
Read More

Financings for April 22, 2022

April 22, 2022
Biopharmas raising money in public or private financings, Helix, Noxxon.
Read More

Financings for April 21, 2022

April 21, 2022
Biopharmas raising money in public or private financings, including: Bristol Myers Squibb, Dermata, Octant, Xinvento.
Read More
Previous 1 2 … 168 169 170 171 172 173 174 175 176 … 314 315 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Pill in immersive interface

    New mechanism of action identified for QC-6352

    BioWorld Science
    QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing